Amgen Inc. (AMGN) News
Filter AMGN News Items
AMGN News Results
|Loading, please wait...|
AMGN News Highlights
- AMGN's 30 day story count now stands at 29.
- Over the past 18 days, the trend for AMGN's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about AMGN are ACT, DRUG and AMG.
Latest AMGN News From Around the Web
Below are the latest news stories about AMGEN INC that investors may wish to consider to help them evaluate AMGN as an investment opportunity.
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Volume growth from Amgen's (AMGN) key drugs like Prolia, Otezla, Repatha and others is expected to have been partially offset by biosimilar/generic competition for mature drugs.
The 2023 Dogs of the Dow feature several stocks investors should consider for their income portfolios.
Passive-income stocks are a proven way to cushion your portfolio against market volatility. What's more, top shelf dividend plays also tend to outperform other asset classes in bull markets. Not all dividend stocks are cut from the same cloth, however.
Most companies currently paying dividends are equipped to do so for the foreseeable future. Only a handful of dividend-paying companies, however, are built to continue dishing out dividends into the distant unknown as unforeseen changes arise. Here's a closer look at three dividend stocks you can safely hold for years.
Insiders who sold Amgen Inc.'s (NASDAQ:AMGN) earlier this year didn't have to weather this week's 3.1% slide
Amgen Inc.'s (NASDAQ:AMGN) value has fallen 3.1% in the last week, but insiders who sold US$5.2m worth of stock over...
The following slide deck was published by Amgen Inc.
In the latest trading session, Amgen (AMGN) closed at $263.24, marking a +0.46% move from the previous day.
Bristol Myers Squibb Company: The Robert A. Winn Diversity in Clinical Trials Award Program Established by the Bristol Myers Squibb Foundation To Expand With Amgen''s Commitment of $8 Million
Amgen Joins Gilead Sciences as a Program SupporterApplications Now Open for Physicians and Medical StudentsOriginally published on Bristol Myers Squibb News & PerspectivesPRINCETON, NJ / ACCESSWIRE…
Amgen (AMGN) closed at $262.03 in the latest trading session, marking a -0.89% move from the prior day.